Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C32H44F3N3O2S
CAS Number:
Molecular Weight:
591.77
MDL number:
UNSPSC Code:
41116107
EC Number:
225-672-4
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
fluphenazine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
FC(F)(F)c1cc2c(cc1)Sc3c(cccc3)N2CCCN4CCN(CC4)CCOC(=O)CCCCCCCCC
InChI
1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3
InChI key
VIQCGTZFEYDQMR-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Fluphenazine decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Oral - Repr. 2
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Janice Charles et al.
Australian family physician, 35(3), 88-89 (2006-03-10)
The BEACH program, a continuous national study of general practice activity in Australia, gives us an overview of consultations involving the management of psychoses. In this analysis we have included schizophrenia, affective disorders/bipolar, organic psychoses, and senile psychoses, with undefined
Rajaprabhakaran Rajarethinam et al.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 10(4 Pt 2), 416-419 (2009-06-06)
Aripiprazole, a partial dopamine agonist has been reported to help reduce symptoms of tardive dyskinesia (TD). In a prospective, open label study of a series of cases, we examined the effectiveness of aripiprazole in reducing TD symptoms. Six clinically stable
Mis-deca-n identity?
Elizabeth A S Giugni et al.
The Medical journal of Australia, 187(6), 370-370 (2007-09-19)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| F0260000 | 04061838820457 |